| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 174 | 2023 | 828 | 22.930 |
Why?
|
| Severity of Illness Index | 74 | 2023 | 930 | 7.440 |
Why?
|
| Movement Disorders | 24 | 2023 | 90 | 6.810 |
Why?
|
| Hallucinations | 22 | 2023 | 61 | 5.260 |
Why?
|
| Neurology | 20 | 2022 | 53 | 5.130 |
Why?
|
| Disability Evaluation | 21 | 2022 | 287 | 4.990 |
Why?
|
| Antiparkinson Agents | 25 | 2023 | 65 | 4.030 |
Why?
|
| Humans | 239 | 2023 | 26049 | 3.400 |
Why?
|
| Dyskinesia, Drug-Induced | 12 | 2023 | 21 | 3.080 |
Why?
|
| Societies, Medical | 17 | 2022 | 146 | 3.020 |
Why?
|
| Neurologic Examination | 13 | 2016 | 112 | 2.680 |
Why?
|
| Psychometrics | 18 | 2020 | 225 | 2.370 |
Why?
|
| Dyskinesias | 11 | 2021 | 21 | 2.300 |
Why?
|
| Psychiatric Status Rating Scales | 16 | 2021 | 304 | 2.150 |
Why?
|
| Deep Brain Stimulation | 5 | 2022 | 40 | 1.950 |
Why?
|
| History, 19th Century | 24 | 2022 | 29 | 1.880 |
Why?
|
| Neuropsychological Tests | 19 | 2022 | 1228 | 1.870 |
Why?
|
| Male | 102 | 2022 | 14025 | 1.850 |
Why?
|
| Tremor | 12 | 2023 | 117 | 1.780 |
Why?
|
| Placebo Effect | 8 | 2020 | 19 | 1.760 |
Why?
|
| Female | 99 | 2022 | 14411 | 1.750 |
Why?
|
| Aged | 79 | 2022 | 8719 | 1.700 |
Why?
|
| Surveys and Questionnaires | 21 | 2017 | 1066 | 1.650 |
Why?
|
| Middle Aged | 75 | 2022 | 8511 | 1.610 |
Why?
|
| Reproducibility of Results | 32 | 2021 | 670 | 1.580 |
Why?
|
| Sleep Wake Disorders | 8 | 2014 | 102 | 1.540 |
Why?
|
| Psychotic Disorders | 7 | 2011 | 37 | 1.450 |
Why?
|
| Mental Status and Dementia Tests | 12 | 2023 | 69 | 1.210 |
Why?
|
| Cognition Disorders | 14 | 2018 | 991 | 1.180 |
Why?
|
| Antipsychotic Agents | 8 | 2011 | 57 | 1.180 |
Why?
|
| Disease Progression | 20 | 2021 | 685 | 1.120 |
Why?
|
| Levodopa | 14 | 2023 | 47 | 1.100 |
Why?
|
| Telemedicine | 4 | 2022 | 98 | 1.070 |
Why?
|
| Dementia | 9 | 2014 | 532 | 1.070 |
Why?
|
| Heterozygote | 4 | 2022 | 92 | 1.060 |
Why?
|
| Activities of Daily Living | 14 | 2019 | 523 | 1.010 |
Why?
|
| Glucosylceramidase | 2 | 2022 | 17 | 0.990 |
Why?
|
| Videotape Recording | 10 | 2011 | 27 | 0.980 |
Why?
|
| Evaluation Studies as Topic | 3 | 2010 | 35 | 0.980 |
Why?
|
| Supranuclear Palsy, Progressive | 7 | 2020 | 27 | 0.950 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 2 | 2020 | 5 | 0.890 |
Why?
|
| Torticollis | 5 | 2021 | 12 | 0.860 |
Why?
|
| History, 20th Century | 13 | 2014 | 45 | 0.830 |
Why?
|
| Subthalamic Nucleus | 2 | 2022 | 20 | 0.810 |
Why?
|
| Gait Disorders, Neurologic | 5 | 2016 | 139 | 0.790 |
Why?
|
| Emotions | 2 | 2015 | 79 | 0.790 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 4674 | 0.770 |
Why?
|
| Teaching | 3 | 2009 | 53 | 0.760 |
Why?
|
| Mentoring | 1 | 2022 | 30 | 0.760 |
Why?
|
| Brain | 8 | 2023 | 1647 | 0.760 |
Why?
|
| Neuroprotective Agents | 3 | 2014 | 51 | 0.750 |
Why?
|
| Movement | 5 | 2018 | 108 | 0.740 |
Why?
|
| Postural Balance | 4 | 2018 | 117 | 0.720 |
Why?
|
| Apathy | 1 | 2020 | 3 | 0.720 |
Why?
|
| Vibration | 2 | 2012 | 26 | 0.710 |
Why?
|
| Quality of Life | 8 | 2018 | 609 | 0.690 |
Why?
|
| Cerebral Cortex | 4 | 2020 | 159 | 0.690 |
Why?
|
| Depressive Disorder | 2 | 2013 | 167 | 0.680 |
Why?
|
| Fatigue | 3 | 2016 | 56 | 0.660 |
Why?
|
| Forensic Psychiatry | 2 | 2013 | 3 | 0.660 |
Why?
|
| France | 7 | 2022 | 19 | 0.660 |
Why?
|
| Nervous System Diseases | 5 | 2020 | 116 | 0.650 |
Why?
|
| Amantadine | 3 | 2017 | 4 | 0.630 |
Why?
|
| Double-Blind Method | 14 | 2021 | 399 | 0.630 |
Why?
|
| Biomedical Research | 3 | 2016 | 60 | 0.630 |
Why?
|
| Nocebo Effect | 1 | 2018 | 1 | 0.630 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 36 | 0.620 |
Why?
|
| Dopamine Agents | 5 | 2016 | 16 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 275 | 0.600 |
Why?
|
| Uric Acid | 5 | 2022 | 13 | 0.600 |
Why?
|
| Cognition | 4 | 2022 | 1301 | 0.590 |
Why?
|
| Longitudinal Studies | 13 | 2021 | 1344 | 0.580 |
Why?
|
| Clinical Trials as Topic | 9 | 2012 | 216 | 0.580 |
Why?
|
| Societies, Scientific | 4 | 2015 | 9 | 0.560 |
Why?
|
| Adult | 24 | 2020 | 7367 | 0.560 |
Why?
|
| Anticonvulsants | 1 | 2017 | 54 | 0.560 |
Why?
|
| Huntington Disease | 4 | 2018 | 50 | 0.550 |
Why?
|
| Factor Analysis, Statistical | 8 | 2023 | 61 | 0.540 |
Why?
|
| Placebos | 4 | 2012 | 66 | 0.540 |
Why?
|
| Hospitals, University | 2 | 2014 | 26 | 0.530 |
Why?
|
| Depression | 4 | 2020 | 408 | 0.520 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 172 | 0.520 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 853 | 0.510 |
Why?
|
| Compulsive Behavior | 2 | 2019 | 3 | 0.510 |
Why?
|
| Research Design | 3 | 2015 | 181 | 0.500 |
Why?
|
| Amygdala | 1 | 2015 | 40 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2014 | 1140 | 0.500 |
Why?
|
| Dopamine | 5 | 2011 | 79 | 0.500 |
Why?
|
| Fragile X Syndrome | 4 | 2009 | 192 | 0.500 |
Why?
|
| Motor Skills | 3 | 2020 | 52 | 0.490 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 485 | 0.480 |
Why?
|
| Visual Pathways | 2 | 2014 | 5 | 0.480 |
Why?
|
| Health Planning Guidelines | 3 | 2013 | 6 | 0.470 |
Why?
|
| Dopamine Agonists | 2 | 2011 | 17 | 0.460 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 1713 | 0.460 |
Why?
|
| Blindness | 1 | 2014 | 12 | 0.460 |
Why?
|
| Dystonia | 3 | 2013 | 15 | 0.450 |
Why?
|
| Nerve Net | 1 | 2014 | 46 | 0.440 |
Why?
|
| Cohort Studies | 11 | 2018 | 1829 | 0.440 |
Why?
|
| Cholecystokinin | 2 | 2011 | 7 | 0.430 |
Why?
|
| Homicide | 1 | 2013 | 4 | 0.430 |
Why?
|
| Suicide | 1 | 2013 | 10 | 0.430 |
Why?
|
| Mutation | 3 | 2022 | 311 | 0.430 |
Why?
|
| Ataxia | 2 | 2005 | 77 | 0.420 |
Why?
|
| Language | 4 | 2021 | 62 | 0.420 |
Why?
|
| International Cooperation | 6 | 2018 | 22 | 0.410 |
Why?
|
| Evidence-Based Medicine | 4 | 2011 | 186 | 0.410 |
Why?
|
| Multiple System Atrophy | 4 | 2022 | 36 | 0.410 |
Why?
|
| Muscle Stretching Exercises | 1 | 2012 | 3 | 0.400 |
Why?
|
| Resistance Training | 1 | 2012 | 7 | 0.400 |
Why?
|
| Tai Ji | 1 | 2012 | 9 | 0.400 |
Why?
|
| Inosine | 4 | 2022 | 4 | 0.400 |
Why?
|
| Weights and Measures | 2 | 2011 | 6 | 0.400 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 127 | 0.400 |
Why?
|
| Neurosurgical Procedures | 3 | 2012 | 124 | 0.400 |
Why?
|
| Disease Management | 1 | 2013 | 108 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2011 | 305 | 0.390 |
Why?
|
| Tourette Syndrome | 2 | 2009 | 13 | 0.390 |
Why?
|
| Substantia Nigra | 5 | 2016 | 113 | 0.390 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 69 | 0.380 |
Why?
|
| Prevalence | 6 | 2010 | 433 | 0.380 |
Why?
|
| Fetal Tissue Transplantation | 3 | 2008 | 25 | 0.380 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 4 | 0.370 |
Why?
|
| Behavioral Symptoms | 3 | 2017 | 10 | 0.370 |
Why?
|
| Anxiety | 2 | 2010 | 136 | 0.370 |
Why?
|
| Publishing | 2 | 2008 | 35 | 0.360 |
Why?
|
| Carbazoles | 1 | 2010 | 6 | 0.360 |
Why?
|
| Editorial Policies | 2 | 2007 | 5 | 0.360 |
Why?
|
| Animals | 12 | 2022 | 3391 | 0.350 |
Why?
|
| Mercury Compounds | 1 | 2010 | 1 | 0.350 |
Why?
|
| Databases, Factual | 4 | 2022 | 325 | 0.350 |
Why?
|
| Authorship | 2 | 2007 | 14 | 0.350 |
Why?
|
| Medical Illustration | 1 | 2010 | 14 | 0.350 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 32 | 0.350 |
Why?
|
| Neuroanatomy | 1 | 2010 | 2 | 0.340 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2007 | 11 | 0.340 |
Why?
|
| Microbiology | 1 | 2009 | 2 | 0.340 |
Why?
|
| Motion Pictures | 2 | 2006 | 4 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2019 | 3293 | 0.330 |
Why?
|
| Cognitive Dysfunction | 3 | 2014 | 1026 | 0.330 |
Why?
|
| Consensus | 2 | 2023 | 83 | 0.330 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 4 | 0.330 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 10 | 0.320 |
Why?
|
| Hypokinesia | 1 | 2009 | 23 | 0.320 |
Why?
|
| Communicable Diseases | 1 | 2009 | 22 | 0.320 |
Why?
|
| Tics | 1 | 2008 | 4 | 0.320 |
Why?
|
| Psychomotor Performance | 3 | 2013 | 203 | 0.320 |
Why?
|
| United States | 9 | 2014 | 1981 | 0.310 |
Why?
|
| Drug Monitoring | 1 | 2008 | 17 | 0.310 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2008 | 3 | 0.310 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 39 | 0.310 |
Why?
|
| History, 21st Century | 3 | 2014 | 23 | 0.310 |
Why?
|
| Indans | 2 | 2005 | 7 | 0.310 |
Why?
|
| Tauopathies | 1 | 2008 | 20 | 0.300 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.300 |
Why?
|
| Documentation | 1 | 2008 | 26 | 0.300 |
Why?
|
| Motivation | 1 | 2008 | 92 | 0.300 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 133 | 0.300 |
Why?
|
| Work | 1 | 2007 | 7 | 0.290 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2023 | 31 | 0.290 |
Why?
|
| Disclosure | 1 | 2007 | 12 | 0.290 |
Why?
|
| Deglutition Disorders | 2 | 2009 | 35 | 0.290 |
Why?
|
| Neoplasms | 1 | 2010 | 219 | 0.290 |
Why?
|
| Malingering | 1 | 2007 | 1 | 0.290 |
Why?
|
| Conversion Disorder | 1 | 2007 | 4 | 0.290 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 157 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 315 | 0.290 |
Why?
|
| Muscle Rigidity | 1 | 2007 | 21 | 0.280 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2007 | 2 | 0.280 |
Why?
|
| Education | 1 | 2007 | 45 | 0.280 |
Why?
|
| Confidentiality | 1 | 2007 | 6 | 0.280 |
Why?
|
| Time Factors | 7 | 2019 | 1364 | 0.280 |
Why?
|
| Pain | 2 | 2021 | 383 | 0.280 |
Why?
|
| Communication | 1 | 2008 | 102 | 0.280 |
Why?
|
| Age of Onset | 3 | 2003 | 92 | 0.280 |
Why?
|
| Paris | 4 | 2010 | 4 | 0.270 |
Why?
|
| Photography | 1 | 2006 | 15 | 0.270 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 98 | 0.270 |
Why?
|
| Guidelines as Topic | 3 | 2013 | 62 | 0.270 |
Why?
|
| Aging | 2 | 2008 | 1540 | 0.270 |
Why?
|
| Point Mutation | 2 | 2003 | 27 | 0.270 |
Why?
|
| Parkinsonian Disorders | 2 | 2007 | 219 | 0.270 |
Why?
|
| Seasons | 1 | 2006 | 21 | 0.260 |
Why?
|
| Charcot-Marie-Tooth Disease | 2 | 2003 | 3 | 0.260 |
Why?
|
| Literature, Modern | 1 | 2006 | 2 | 0.260 |
Why?
|
| Medicine in Literature | 1 | 2006 | 2 | 0.260 |
Why?
|
| Psychophysiologic Disorders | 1 | 2005 | 7 | 0.260 |
Why?
|
| Case-Control Studies | 5 | 2014 | 550 | 0.260 |
Why?
|
| Adolescent | 10 | 2020 | 2064 | 0.260 |
Why?
|
| Psychotherapy | 1 | 2005 | 35 | 0.250 |
Why?
|
| Globus Pallidus | 1 | 2005 | 11 | 0.250 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2005 | 17 | 0.250 |
Why?
|
| Mentors | 2 | 2022 | 42 | 0.250 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2005 | 2 | 0.240 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 9 | 0.240 |
Why?
|
| Time | 1 | 2005 | 12 | 0.240 |
Why?
|
| Siblings | 1 | 2005 | 15 | 0.240 |
Why?
|
| Risk Factors | 9 | 2010 | 2246 | 0.230 |
Why?
|
| Space Perception | 2 | 2014 | 24 | 0.230 |
Why?
|
| Certification | 1 | 2004 | 45 | 0.230 |
Why?
|
| Advisory Committees | 3 | 2014 | 22 | 0.230 |
Why?
|
| Tic Disorders | 2 | 2017 | 2 | 0.230 |
Why?
|
| Biomarkers | 7 | 2021 | 551 | 0.230 |
Why?
|
| Feasibility Studies | 4 | 2009 | 202 | 0.230 |
Why?
|
| Mitochondria | 2 | 2020 | 57 | 0.230 |
Why?
|
| Diagnosis, Differential | 5 | 2007 | 342 | 0.220 |
Why?
|
| Walkers | 1 | 2003 | 2 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 291 | 0.220 |
Why?
|
| Analysis of Variance | 3 | 2013 | 253 | 0.220 |
Why?
|
| Sick Role | 1 | 2003 | 14 | 0.220 |
Why?
|
| Retrospective Studies | 7 | 2021 | 3305 | 0.220 |
Why?
|
| Speech Disorders | 1 | 2003 | 11 | 0.210 |
Why?
|
| Child, Preschool | 5 | 2020 | 589 | 0.210 |
Why?
|
| Prospective Studies | 6 | 2020 | 1663 | 0.210 |
Why?
|
| Reflex, Babinski | 1 | 2002 | 1 | 0.210 |
Why?
|
| Lewy Body Disease | 3 | 2016 | 98 | 0.210 |
Why?
|
| Color Vision Defects | 1 | 2002 | 4 | 0.210 |
Why?
|
| Contrast Sensitivity | 1 | 2002 | 7 | 0.210 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 138 | 0.200 |
Why?
|
| Neurosecretory Systems | 1 | 2022 | 9 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 10 | 0.200 |
Why?
|
| Mesencephalon | 2 | 2017 | 26 | 0.200 |
Why?
|
| Single-Blind Method | 3 | 2008 | 105 | 0.200 |
Why?
|
| Loneliness | 1 | 2022 | 55 | 0.200 |
Why?
|
| Myoclonus | 1 | 2002 | 10 | 0.200 |
Why?
|
| Serotonin | 1 | 2002 | 24 | 0.200 |
Why?
|
| Peer Group | 1 | 2022 | 35 | 0.200 |
Why?
|
| Child | 6 | 2020 | 1229 | 0.190 |
Why?
|
| Odds Ratio | 3 | 2008 | 260 | 0.190 |
Why?
|
| Office Visits | 1 | 2021 | 12 | 0.190 |
Why?
|
| Atrophy | 3 | 2014 | 90 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 457 | 0.190 |
Why?
|
| Basal Ganglia | 2 | 2013 | 15 | 0.180 |
Why?
|
| Mental Status Schedule | 3 | 2013 | 94 | 0.180 |
Why?
|
| Dental Care for Disabled | 1 | 2020 | 1 | 0.180 |
Why?
|
| Dental Instruments | 1 | 2020 | 1 | 0.180 |
Why?
|
| Diagnosis, Oral | 1 | 2020 | 1 | 0.180 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 53 | 0.180 |
Why?
|
| PubMed | 3 | 2011 | 10 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2009 | 81 | 0.180 |
Why?
|
| Axons | 1 | 2020 | 24 | 0.180 |
Why?
|
| Neurons | 3 | 2020 | 309 | 0.170 |
Why?
|
| Age Factors | 2 | 2017 | 744 | 0.170 |
Why?
|
| United Kingdom | 3 | 2018 | 46 | 0.170 |
Why?
|
| Observer Variation | 3 | 2011 | 93 | 0.170 |
Why?
|
| Head | 1 | 2020 | 22 | 0.170 |
Why?
|
| Neck | 1 | 2020 | 26 | 0.170 |
Why?
|
| Sample Size | 2 | 2013 | 20 | 0.170 |
Why?
|
| Impulsive Behavior | 1 | 2019 | 14 | 0.160 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 117 | 0.160 |
Why?
|
| Biological Evolution | 1 | 2019 | 9 | 0.160 |
Why?
|
| Health Status | 3 | 2013 | 212 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.160 |
Why?
|
| Organic Chemicals | 3 | 2008 | 6 | 0.160 |
Why?
|
| Mobile Applications | 1 | 2019 | 24 | 0.160 |
Why?
|
| Benzothiazoles | 2 | 2011 | 5 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 38 | 0.160 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2018 | 2 | 0.160 |
Why?
|
| History, 18th Century | 1 | 2018 | 5 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2020 | 124 | 0.160 |
Why?
|
| Piperazines | 2 | 2011 | 76 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 39 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 82 | 0.150 |
Why?
|
| Corneal Stroma | 1 | 2018 | 1 | 0.150 |
Why?
|
| Riboflavin | 1 | 2018 | 1 | 0.150 |
Why?
|
| Keratoconus | 1 | 2018 | 2 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2019 | 118 | 0.150 |
Why?
|
| Photosensitizing Agents | 1 | 2018 | 4 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 85 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2018 | 4 | 0.150 |
Why?
|
| alpha-Synuclein | 2 | 2017 | 122 | 0.150 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 15 | 0.150 |
Why?
|
| Fragile X Mental Retardation Protein | 3 | 2009 | 118 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 238 | 0.150 |
Why?
|
| Executive Function | 3 | 2014 | 114 | 0.150 |
Why?
|
| Mass Screening | 3 | 2018 | 166 | 0.150 |
Why?
|
| Attention | 3 | 2014 | 126 | 0.150 |
Why?
|
| Seveso Accidental Release | 1 | 2017 | 1 | 0.140 |
Why?
|
| Checklist | 2 | 2022 | 36 | 0.140 |
Why?
|
| Comorbidity | 3 | 2010 | 466 | 0.140 |
Why?
|
| Research | 2 | 2007 | 35 | 0.140 |
Why?
|
| Genotype | 5 | 2011 | 336 | 0.140 |
Why?
|
| Program Evaluation | 2 | 2010 | 124 | 0.140 |
Why?
|
| Linear Models | 2 | 2014 | 240 | 0.140 |
Why?
|
| Graft Survival | 1 | 2017 | 92 | 0.130 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Memory Disorders | 3 | 2014 | 166 | 0.130 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2016 | 2 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2018 | 253 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 36 | 0.130 |
Why?
|
| Dopaminergic Neurons | 1 | 2017 | 41 | 0.130 |
Why?
|
| Caregivers | 1 | 2018 | 145 | 0.130 |
Why?
|
| Phylogeny | 1 | 2015 | 46 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 55 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2007 | 373 | 0.130 |
Why?
|
| Prodromal Symptoms | 1 | 2015 | 17 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2011 | 57 | 0.130 |
Why?
|
| Axonal Transport | 1 | 2015 | 7 | 0.130 |
Why?
|
| Putamen | 1 | 2015 | 21 | 0.120 |
Why?
|
| Neurturin | 1 | 2015 | 23 | 0.120 |
Why?
|
| Self Care | 2 | 2008 | 92 | 0.120 |
Why?
|
| Lewy Bodies | 2 | 2014 | 193 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2015 | 55 | 0.120 |
Why?
|
| Young Adult | 4 | 2020 | 1853 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 447 | 0.120 |
Why?
|
| Translations | 3 | 2021 | 12 | 0.120 |
Why?
|
| Syndrome | 2 | 2006 | 73 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 290 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 80 | 0.120 |
Why?
|
| Superior Colliculi | 1 | 2014 | 2 | 0.120 |
Why?
|
| Postal Service | 1 | 2014 | 2 | 0.110 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 99 | 0.110 |
Why?
|
| Selegiline | 2 | 2005 | 4 | 0.110 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 7 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2014 | 123 | 0.110 |
Why?
|
| Video Recording | 2 | 2020 | 33 | 0.110 |
Why?
|
| Ligases | 2 | 2003 | 8 | 0.110 |
Why?
|
| Memory | 2 | 2013 | 300 | 0.110 |
Why?
|
| Essential Tremor | 1 | 2013 | 5 | 0.110 |
Why?
|
| New York City | 1 | 2013 | 14 | 0.110 |
Why?
|
| Acoustic Stimulation | 2 | 2004 | 39 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2003 | 24 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 40 | 0.110 |
Why?
|
| Sensation Disorders | 1 | 2013 | 11 | 0.110 |
Why?
|
| Spouses | 1 | 2013 | 25 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 46 | 0.110 |
Why?
|
| Constipation | 2 | 2011 | 18 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 125 | 0.110 |
Why?
|
| Hand Strength | 1 | 2013 | 56 | 0.100 |
Why?
|
| Calibration | 1 | 2012 | 16 | 0.100 |
Why?
|
| Observation | 1 | 2012 | 13 | 0.100 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2012 | 1 | 0.100 |
Why?
|
| Prognosis | 2 | 2021 | 750 | 0.100 |
Why?
|
| Amnesia | 1 | 2012 | 25 | 0.100 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 298 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 186 | 0.100 |
Why?
|
| Brain Tissue Transplantation | 3 | 2017 | 18 | 0.100 |
Why?
|
| Entorhinal Cortex | 1 | 2012 | 36 | 0.100 |
Why?
|
| Dysbiosis | 2 | 2022 | 55 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2011 | 1 | 0.100 |
Why?
|
| Clozapine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 11 | 0.090 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 16 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 29 | 0.090 |
Why?
|
| Poland | 2 | 2021 | 4 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 84 | 0.090 |
Why?
|
| Mental Disorders | 2 | 2011 | 126 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2012 | 111 | 0.090 |
Why?
|
| Polysomnography | 1 | 2010 | 69 | 0.090 |
Why?
|
| Osteoarthritis, Knee | 1 | 2015 | 360 | 0.090 |
Why?
|
| Sleep | 1 | 2013 | 255 | 0.090 |
Why?
|
| Self Report | 1 | 2011 | 203 | 0.090 |
Why?
|
| Posture | 2 | 2021 | 63 | 0.090 |
Why?
|
| Survivors | 1 | 2010 | 54 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 156 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 121 | 0.090 |
Why?
|
| Algorithms | 1 | 2012 | 358 | 0.090 |
Why?
|
| Illinois | 1 | 2010 | 227 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Head Protective Devices | 1 | 2009 | 3 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2009 | 56 | 0.080 |
Why?
|
| Carbidopa | 1 | 2009 | 5 | 0.080 |
Why?
|
| Illusions | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 12 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 16 | 0.080 |
Why?
|
| Sialorrhea | 1 | 2009 | 2 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 90 | 0.080 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2009 | 18 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 34 | 0.080 |
Why?
|
| Israel | 2 | 2020 | 14 | 0.080 |
Why?
|
| Europe | 2 | 2006 | 65 | 0.080 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 15 | 0.080 |
Why?
|
| Biomechanical Phenomena | 2 | 2009 | 639 | 0.080 |
Why?
|
| Cell Transplantation | 1 | 2009 | 22 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 94 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2010 | 416 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2008 | 7 | 0.080 |
Why?
|
| ROC Curve | 3 | 2013 | 132 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 41 | 0.080 |
Why?
|
| Reference Values | 2 | 2006 | 184 | 0.080 |
Why?
|
| Delusions | 1 | 2008 | 9 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 84 | 0.080 |
Why?
|
| Swine | 1 | 2008 | 62 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 52 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 714 | 0.070 |
Why?
|
| Logistic Models | 2 | 2013 | 362 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 568 | 0.070 |
Why?
|
| Catalepsy | 1 | 2007 | 1 | 0.070 |
Why?
|
| Deception | 1 | 2007 | 1 | 0.070 |
Why?
|
| Neurasthenia | 1 | 2007 | 1 | 0.070 |
Why?
|
| Neurophysiology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hospitals, Military | 1 | 2007 | 3 | 0.070 |
Why?
|
| Philadelphia | 1 | 2007 | 4 | 0.070 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 4 | 0.070 |
Why?
|
| Review Literature as Topic | 1 | 2007 | 10 | 0.070 |
Why?
|
| Warfare | 1 | 2007 | 10 | 0.070 |
Why?
|
| Military Medicine | 1 | 2007 | 8 | 0.070 |
Why?
|
| Hospitals, Psychiatric | 1 | 2007 | 13 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 327 | 0.070 |
Why?
|
| Contracture | 1 | 2007 | 13 | 0.070 |
Why?
|
| Military Personnel | 1 | 2007 | 28 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 37 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2007 | 32 | 0.070 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2007 | 4 | 0.070 |
Why?
|
| Quinolones | 1 | 2006 | 12 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Germany | 1 | 2006 | 6 | 0.070 |
Why?
|
| Patient Selection | 2 | 2009 | 193 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2023 | 36 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 49 | 0.070 |
Why?
|
| Darkness | 1 | 2006 | 15 | 0.070 |
Why?
|
| Parkinson Disease, Postencephalitic | 1 | 2006 | 1 | 0.070 |
Why?
|
| Interview, Psychological | 1 | 2006 | 34 | 0.070 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 15 | 0.060 |
Why?
|
| Light | 1 | 2006 | 60 | 0.060 |
Why?
|
| Inpatients | 1 | 2007 | 132 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 37 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 170 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 77 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2003 | 264 | 0.060 |
Why?
|
| Nitrophenols | 1 | 2005 | 1 | 0.060 |
Why?
|
| Piribedil | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dihydroergocryptine | 1 | 2005 | 1 | 0.060 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2005 | 1 | 0.060 |
Why?
|
| Ergolines | 1 | 2005 | 2 | 0.060 |
Why?
|
| Lisuride | 1 | 2005 | 2 | 0.060 |
Why?
|
| Pergolide | 1 | 2005 | 3 | 0.060 |
Why?
|
| Apomorphine | 1 | 2005 | 4 | 0.060 |
Why?
|
| Bromocriptine | 1 | 2005 | 5 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 93 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 18 | 0.060 |
Why?
|
| Benzophenones | 1 | 2005 | 28 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 34 | 0.060 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 245 | 0.060 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 12 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 23 | 0.060 |
Why?
|
| Alleles | 4 | 2009 | 202 | 0.060 |
Why?
|
| Visual Perception | 1 | 2005 | 35 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2005 | 41 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2005 | 33 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Somnambulism | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hypnosis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2004 | 11 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 9 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 166 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 4 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 149 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 78 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2005 | 120 | 0.060 |
Why?
|
| Immobilization | 1 | 2003 | 14 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2003 | 9 | 0.060 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2003 | 4 | 0.060 |
Why?
|
| Brain Mapping | 1 | 2005 | 168 | 0.060 |
Why?
|
| Workers' Compensation | 1 | 2004 | 67 | 0.060 |
Why?
|
| Reality Testing | 1 | 2003 | 2 | 0.050 |
Why?
|
| Life Tables | 1 | 2003 | 3 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 8 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2003 | 21 | 0.050 |
Why?
|
| Writing | 1 | 2003 | 18 | 0.050 |
Why?
|
| Paintings | 1 | 2002 | 2 | 0.050 |
Why?
|
| Medicine in the Arts | 1 | 2002 | 2 | 0.050 |
Why?
|
| Prebiotics | 1 | 2023 | 21 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 304 | 0.050 |
Why?
|
| Pyramidal Tracts | 1 | 2002 | 4 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 34 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2003 | 54 | 0.050 |
Why?
|
| Cause of Death | 1 | 2003 | 57 | 0.050 |
Why?
|
| Vision Tests | 1 | 2002 | 5 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 41 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2003 | 73 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 105 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 22 | 0.050 |
Why?
|
| Physicians, Women | 1 | 2002 | 17 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 39 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 6 | 0.050 |
Why?
|
| Tocopherols | 1 | 2002 | 7 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2002 | 25 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 140 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 182 | 0.050 |
Why?
|
| Bias | 1 | 2022 | 35 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 74 | 0.050 |
Why?
|
| Hypoxia | 1 | 2002 | 32 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 6 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2021 | 4 | 0.050 |
Why?
|
| Finland | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 106 | 0.050 |
Why?
|
| Touch | 1 | 2021 | 8 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 68 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 7 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 148 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 29 | 0.050 |
Why?
|
| Dental Anxiety | 1 | 2020 | 1 | 0.050 |
Why?
|
| Alzheimer Disease | 2 | 2003 | 2075 | 0.050 |
Why?
|
| Life Style | 1 | 2022 | 187 | 0.050 |
Why?
|
| Mouth | 1 | 2020 | 12 | 0.050 |
Why?
|
| Austria | 1 | 2020 | 3 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2003 | 622 | 0.040 |
Why?
|
| Rats | 1 | 2002 | 598 | 0.040 |
Why?
|
| Fingers | 1 | 2020 | 10 | 0.040 |
Why?
|
| Stroke | 1 | 2002 | 254 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 522 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 9 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 17 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 15 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2018 | 1 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2018 | 2 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 16 | 0.040 |
Why?
|
| Collagen | 1 | 2018 | 80 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 37 | 0.040 |
Why?
|
| Translating | 1 | 2017 | 3 | 0.040 |
Why?
|
| Phenotype | 2 | 2009 | 291 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2017 | 49 | 0.030 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 18 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 22 | 0.030 |
Why?
|
| Forecasting | 2 | 2007 | 91 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 121 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 23 | 0.030 |
Why?
|
| Dependovirus | 1 | 2015 | 37 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 85 | 0.030 |
Why?
|
| Remote Consultation | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nursing Care | 1 | 2014 | 21 | 0.030 |
Why?
|
| Patient Care | 1 | 2014 | 29 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 110 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 52 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2013 | 20 | 0.030 |
Why?
|
| Anisotropy | 1 | 2013 | 51 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 104 | 0.030 |
Why?
|
| Haplotypes | 2 | 2003 | 55 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2003 | 5 | 0.030 |
Why?
|
| Lod Score | 2 | 2003 | 12 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2003 | 26 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 64 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 13 | 0.030 |
Why?
|
| Organ Size | 1 | 2012 | 95 | 0.020 |
Why?
|
| Fetal Stem Cells | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pallidotomy | 1 | 2011 | 1 | 0.020 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 2 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2011 | 5 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 21 | 0.020 |
Why?
|
| Thalamus | 1 | 2011 | 16 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 2011 | 7 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 21 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2011 | 25 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2011 | 25 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 13 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 27 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 22 | 0.020 |
Why?
|
| Norway | 1 | 2010 | 1 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 261 | 0.020 |
Why?
|
| Lamins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Physicians | 1 | 2011 | 108 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 55 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 93 | 0.020 |
Why?
|
| Tablets | 1 | 2009 | 6 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2009 | 33 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 59 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 449 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 314 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 265 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 475 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 412 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2007 | 47 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2006 | 7 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2006 | 7 | 0.020 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2007 | 46 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 17 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2007 | 98 | 0.020 |
Why?
|
| Prodrugs | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 610 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2006 | 15 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2006 | 12 | 0.020 |
Why?
|
| Spain | 1 | 2005 | 9 | 0.020 |
Why?
|
| Awareness | 1 | 2006 | 36 | 0.020 |
Why?
|
| Speech | 1 | 2005 | 22 | 0.020 |
Why?
|
| Demography | 1 | 2005 | 71 | 0.020 |
Why?
|
| Reaction Time | 1 | 2006 | 109 | 0.020 |
Why?
|
| Mice | 1 | 2009 | 1281 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 76 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2006 | 378 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2005 | 20 | 0.020 |
Why?
|
| Hysteria | 1 | 2004 | 1 | 0.010 |
Why?
|
| Romania | 1 | 2004 | 1 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2004 | 16 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 30 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2003 | 34 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 9 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 49 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 12 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 111 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2003 | 62 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 45 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 25 | 0.010 |
Why?
|
| Walking | 1 | 2005 | 257 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 162 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2002 | 4 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2002 | 26 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2002 | 24 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 251 | 0.010 |
Why?
|